• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4841056)   Today's Articles (10978)
For: Huang H, Wu D, Miao H, Tang Y, Liu C, Fang H, Meng X, Wang S, Zhu Q, Wang X, Du J, Yang Z, Li N, Xu B, He J. Accelerating the integration of China into the global development of innovative anticancer drugs. Lancet Oncol 2022;23:e515-e520. [PMID: 36328025 DOI: 10.1016/s1470-2045(22)00483-1] [Citation(s) in RCA: 16] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2022] [Revised: 07/11/2022] [Accepted: 07/15/2022] [Indexed: 11/06/2022]
Number Cited by Other Article(s)
1
Ding J, Huang H, Wang Y, Hou Y, Zhao G, Cai Y, Wang S, Zhang X, Li N. Expediting the integration of China into the global rare disease drug development and approval. Sci Bull (Beijing) 2025:S2095-9273(25)00394-9. [PMID: 40328602 DOI: 10.1016/j.scib.2025.04.036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2025] [Revised: 03/02/2025] [Accepted: 03/17/2025] [Indexed: 05/08/2025]
2
Li H, Li Q, Zheng Y, He S, Teng Y, Cao M, Tan N, Wang J, Li T, Zuo T, Gao Z, Li K, Chen W. Profiles and disparities of the global cancer and subtypes burden among adults aged 65 years and older: changing patterns in incidence and mortality, 1990-2021. Sci Bull (Beijing) 2025;70:1139-1151. [PMID: 40023725 DOI: 10.1016/j.scib.2025.02.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2024] [Revised: 12/19/2024] [Accepted: 01/22/2025] [Indexed: 03/04/2025]
3
Wang Y, Wang S, Li N. Accelerating the clinical translation of CD70-targeted chimeric antigen receptor-based cell therapies in oncology: A comprehensive clinical investigation panorama analysis based on the Trialtrove database. Cancer Lett 2025;614:217510. [PMID: 39922452 DOI: 10.1016/j.canlet.2025.217510] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2024] [Revised: 01/20/2025] [Accepted: 01/27/2025] [Indexed: 02/10/2025]
4
Xu Y, Guo Q, Chen Z, Liu Y, Yang Y. Overview of new indications for novel drugs approved in China between 2018 and 2024. Drug Discov Today 2025;30:104342. [PMID: 40122451 DOI: 10.1016/j.drudis.2025.104342] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2024] [Revised: 03/07/2025] [Accepted: 03/18/2025] [Indexed: 03/25/2025]
5
Zhu X, Zhang J. Regulatory efforts to address the access gap for foreign new drugs in China: the priority review program and related policies. Glob Health Res Policy 2025;10:7. [PMID: 40001257 PMCID: PMC11853587 DOI: 10.1186/s41256-024-00396-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2024] [Accepted: 11/28/2024] [Indexed: 02/27/2025]  Open
6
Liu J, Farrow M, Seymour L, Desai J, Loong HH, Ivy P, Koyoma T, Cook N, Blagden S, Garralda E, Massard C, Tolcher AW, Adashek JJ, Zhang L, Zhao S, Shen L, Kurzrock R, El-Deiry WS, Subbiah V, Joshua AM. Accelerating the Future of Oncology Drug Development: The Role of Consortia in the Delivery of Precision Oncology Early Phase Clinical Trials. J Clin Oncol 2025;43:735-747. [PMID: 39808749 DOI: 10.1200/jco-24-01534] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2024] [Revised: 10/15/2024] [Accepted: 11/14/2024] [Indexed: 01/16/2025]  Open
7
Ma H, Li J. Impact of HER2-targeting antibody drug conjugates in treatment strategies for patients with breast cancer. Heliyon 2025;11:e41590. [PMID: 39916839 PMCID: PMC11799954 DOI: 10.1016/j.heliyon.2024.e41590] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2024] [Revised: 11/25/2024] [Accepted: 12/30/2024] [Indexed: 02/09/2025]  Open
8
Peng J, Wang Y, Chi Z, Li S, Zhang Y, Li L, Bian D, Zhai Z, Yuan S, Zhang Y, Li W, Ye F, Wang L. Comparative effectiveness and safety of imported and domestic immune checkpoint inhibitors in China: A systematic review and pairwise and network meta-analyses. Pharmacol Res 2024;210:107475. [PMID: 39571771 DOI: 10.1016/j.phrs.2024.107475] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/09/2024] [Revised: 10/07/2024] [Accepted: 10/17/2024] [Indexed: 11/28/2024]
9
Li M, Ka D, Chen Q. Disparities in availability of new cancer drugs worldwide: 1990-2022. BMJ Glob Health 2024;9:e015700. [PMID: 39379168 PMCID: PMC11481112 DOI: 10.1136/bmjgh-2024-015700] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2024] [Accepted: 08/08/2024] [Indexed: 10/10/2024]  Open
10
Li J, Zhang Y, Fu T, Xing G, Cai H, Li K, Xu Y, Tong Y. Clinical advances and challenges associated with TCR-T cell therapy for cancer treatment. Front Immunol 2024;15:1487782. [PMID: 39439803 PMCID: PMC11493697 DOI: 10.3389/fimmu.2024.1487782] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2024] [Accepted: 09/24/2024] [Indexed: 10/25/2024]  Open
11
Lan B, Peng X, Ma F. Questionnaire survey and analysis of drug clinical research implementation capabilities of breast cancer treatment departments in Chinese hospitals. Breast 2024;77:103766. [PMID: 38970984 PMCID: PMC11283010 DOI: 10.1016/j.breast.2024.103766] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2024] [Revised: 06/17/2024] [Accepted: 07/02/2024] [Indexed: 07/08/2024]  Open
12
Chen QA, Ma K, Zhang L, Lin WH, Wu XX, Gao YB. Efficacy and Safety of Anti-Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Antibodies Plus Chemotherapy as First-Line Treatment for NSCLC in the People's Republic of China: a Systematic Review and Meta-Analysis. JTO Clin Res Rep 2024;5:100678. [PMID: 38846810 PMCID: PMC11153918 DOI: 10.1016/j.jtocrr.2024.100678] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2024] [Revised: 04/10/2024] [Accepted: 04/19/2024] [Indexed: 06/09/2024]  Open
13
Huang H, Jia S, Wang X, Miao H, Fang H, He H, Wu D, Tang Y, Li N. Quantitative evaluation of the impact of relaxing eligibility criteria on the risk-benefit profile of drugs for lung cancer based on real-world data. Thorac Cancer 2024;15:1187-1194. [PMID: 38576119 PMCID: PMC11091778 DOI: 10.1111/1759-7714.15269] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2024] [Accepted: 02/12/2024] [Indexed: 04/06/2024]  Open
14
Huang H, Jiang N, Chen W, Tang Y, Li N. A call to rethink the necessity of and challenges facing academic research organizations in the new era of drug innovation in China. Drug Discov Today 2024;29:103925. [PMID: 38403155 DOI: 10.1016/j.drudis.2024.103925] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2023] [Revised: 02/13/2024] [Accepted: 02/19/2024] [Indexed: 02/27/2024]
15
Li J, Zhou J, Wang H, Liu Z, Fan Z, Liu Y, Geng C, Xiao Y, Jiang Z. Trends in Disparities and Transitions of Treatment in Patients With Early Breast Cancer in China and the US, 2011 to 2021. JAMA Netw Open 2023;6:e2321388. [PMID: 37389867 PMCID: PMC10314317 DOI: 10.1001/jamanetworkopen.2023.21388] [Citation(s) in RCA: 12] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/19/2023] [Accepted: 05/16/2023] [Indexed: 07/01/2023]  Open
16
Huang H, Du J, Meng X, Wu D, Yu Y, Wang S, Wang L, Wang W, Tang Y, Li N. Growing research and development of targeted anticancer drugs in China. JOURNAL OF THE NATIONAL CANCER CENTER 2023;3:129-134. [PMID: 39035724 PMCID: PMC11256715 DOI: 10.1016/j.jncc.2023.02.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2022] [Revised: 01/17/2023] [Accepted: 02/20/2023] [Indexed: 01/22/2024]  Open
17
Fang Y, Wang S, Han S, Zhao Y, Yu C, Liu H, Li N. Targeted protein degrader development for cancer: advances, challenges, and opportunities. Trends Pharmacol Sci 2023;44:303-317. [PMID: 37059054 DOI: 10.1016/j.tips.2023.03.003] [Citation(s) in RCA: 43] [Impact Index Per Article: 21.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2023] [Revised: 03/08/2023] [Accepted: 03/08/2023] [Indexed: 04/16/2023]
PrevPage 1 of 1 1Next
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA